Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
$3.64
-2.7%
$3.09
$2.46
$4.15
$311.51M0.25324,012 shs424,024 shs
enGene Holdings Inc. stock logo
ENGN
enGene
$3.81
+0.3%
$3.62
$2.65
$11.00
$194.69M-0.42127,734 shs73,984 shs
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$1.11
-5.1%
$0.99
$0.69
$3.94
$220.00M0.74.82 million shs2.92 million shs
InterCure Ltd. stock logo
INCR
InterCure
$1.50
-3.9%
$1.53
$1.17
$2.62
$71.09M1.1826,075 shs76,959 shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
0.00%+6.38%+15.41%+32.01%+12.92%
enGene Holdings Inc. stock logo
ENGN
enGene
0.00%+6.01%+2.65%-17.09%-57.60%
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
0.00%+17.85%-4.02%-2.42%-52.20%
InterCure Ltd. stock logo
INCR
InterCure
0.00%-0.34%-1.00%+13.36%-35.43%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
2.3282 of 5 stars
3.32.00.00.00.62.51.3
enGene Holdings Inc. stock logo
ENGN
enGene
2.7748 of 5 stars
3.53.00.00.01.52.50.6
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
4.1964 of 5 stars
3.43.00.03.92.61.70.6
InterCure Ltd. stock logo
INCR
InterCure
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
2.50
Moderate Buy$6.0064.84% Upside
enGene Holdings Inc. stock logo
ENGN
enGene
3.00
Buy$23.29511.17% Upside
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
2.80
Moderate Buy$7.00530.63% Upside
InterCure Ltd. stock logo
INCR
InterCure
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest INCR, ENGN, AVIR, and ESPR Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/17/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00
5/7/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$5.00 ➝ $4.00
4/29/2025
enGene Holdings Inc. stock logo
ENGN
enGene
JMP Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Outperform ➝ Market Outperform$18.00 ➝ $18.00
4/25/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
4/25/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$16.00 ➝ $16.00
4/17/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$4.00 ➝ $3.00
4/11/2025
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetEqual Weight ➝ Equal Weight$6.20 ➝ $6.00
4/8/2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$5.00 ➝ $5.00
(Data available from 7/7/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/A$5.20 per shareN/A
enGene Holdings Inc. stock logo
ENGN
enGene
N/AN/AN/AN/A$5.35 per shareN/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
$332.31M0.66$0.02 per share48.70($1.97) per share-0.56
InterCure Ltd. stock logo
INCR
InterCure
$66.28MN/AN/AN/A$2.36 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$168.38M-$1.65N/AN/AN/AN/A-31.26%-29.27%8/6/2025 (Estimated)
enGene Holdings Inc. stock logo
ENGN
enGene
-$55.14M-$1.65N/AN/AN/AN/A-32.60%-28.26%N/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$51.74M-$0.80N/AN/AN/A-59.03%-0.91%-29.47%8/11/2025 (Estimated)
InterCure Ltd. stock logo
INCR
InterCure
-$18.32MN/A0.00N/AN/AN/AN/A8/28/2025 (Estimated)

Latest INCR, ENGN, AVIR, and ESPR Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/10/2025Q2 2025
enGene Holdings Inc. stock logo
ENGN
enGene
-$0.4768-$0.51-$0.0332-$0.51N/AN/A
5/12/2025Q1 2025
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
-$0.56-$0.40+$0.16-$0.40N/AN/A
5/6/2025Q1 2025
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
-$0.18-$0.21-$0.03-$0.21$54.97 million$65.00 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/AN/AN/AN/AN/A
enGene Holdings Inc. stock logo
ENGN
enGene
N/AN/AN/AN/AN/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/AN/AN/AN/AN/A
InterCure Ltd. stock logo
INCR
InterCure
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
N/A
19.94
19.94
enGene Holdings Inc. stock logo
ENGN
enGene
0.09
12.66
12.66
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
N/A
1.18
0.81
InterCure Ltd. stock logo
INCR
InterCure
0.34
1.73
1.18

Institutional Ownership

CompanyInstitutional Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
86.67%
enGene Holdings Inc. stock logo
ENGN
enGene
64.16%
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
47.39%
InterCure Ltd. stock logo
INCR
InterCure
8.34%

Insider Ownership

CompanyInsider Ownership
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
18.10%
enGene Holdings Inc. stock logo
ENGN
enGene
10.40%
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
1.70%
InterCure Ltd. stock logo
INCR
InterCure
N/A
CompanyEmployeesShares OutstandingFree FloatOptionable
Atea Pharmaceuticals, Inc. stock logo
AVIR
Atea Pharmaceuticals
7085.58 million70.09 millionOptionable
enGene Holdings Inc. stock logo
ENGN
enGene
3151.10 million45.79 millionN/A
Esperion Therapeutics, Inc. stock logo
ESPR
Esperion Therapeutics
200198.20 million194.83 millionOptionable
InterCure Ltd. stock logo
INCR
InterCure
350N/AN/AOptionable

Recent News About These Companies

Intercure 3 Warrants (INCR_t3) - Investing.com
Intercure 3 Warrants (INCR_t3) - Investing.com UK
InterCure names Alexander Rabinovich as Chairman, replacing Ehud Barak
InterCure Secures Major Funding to Boost Growth
Cannabis co InterCure raising NIS 66m for Nir Oz facility
Rising High: Exclusive talk with house of brands Carma HoldCo
InterCure Ltd. (INCR)
Electreon Wireless Ltd (ELWS)

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Atea Pharmaceuticals stock logo

Atea Pharmaceuticals NASDAQ:AVIR

$3.64 -0.10 (-2.67%)
As of 04:00 PM Eastern

Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops bemnifosbuvir in combination with ruzasvir, which is in Phase 2 clinical trial, for the treatment of hepatitis C virus (HCV); and a protease inhibitor for the treatment of COVID-19. It has a license agreement with MSD International GmbH for the development, manufacture, and commercialization of Ruzasvir, an NS5A inhibitor, for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.

enGene stock logo

enGene NASDAQ:ENGN

$3.81 +0.01 (+0.26%)
As of 04:00 PM Eastern

enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.

Esperion Therapeutics stock logo

Esperion Therapeutics NASDAQ:ESPR

$1.11 -0.06 (-5.13%)
As of 04:00 PM Eastern

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C. The company's products also include NILEMDO, an ATP Citrate Lyase (ACL) inhibitor that lowers LDL-C and cardiovascular risk by reducing cholesterol biosynthesis and up-regulating the LDL receptors; and NUSTENDI, a bempedoic acid and ezetimibe tablet to treat elevated LDL-C. The company has license and collaboration agreements with Daiichi Sankyo Co. Ltd to; Otsuka Pharmaceutical Co., Ltd; and Daiichi Sankyo Europe GmbH. Esperion Therapeutics, Inc. was incorporated in 2008 and is headquartered in Ann Arbor, Michigan.

InterCure stock logo

InterCure NASDAQ:INCR

$1.50 -0.06 (-3.90%)
As of 03:59 PM Eastern

InterCure Ltd., together with its subsidiaries, engages in the research, cultivation, production, and distribution of pharmaceutical-grade cannabis and cannabis-based products for medical use in Israel and internationally. The company offers dried cannabis inflorescences and cannabis extract mixed with oil. It also invests in biomed sector. The company was incorporated in 1994 and is headquartered in Herzliya, Israel.